Boehringer Shoots For Schizophrenia With PDE9 Inhibitor, Ends Alzheimer's R&D

 
• By Lucie Ellis-Taitt
Fork in the road
Boehringer takes a different path with pipeline drug after Alzheimer's Phase II miss • Source: Shutterstock

More from Clinical Trials

More from R&D